Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
about
Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataSafety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline-based regimensProfile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomitingAdherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysisEvaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting.Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.Synthesis and evaluation of (S)-[(18)F]fesetron in the rat brain as a potential PET imaging agent for serotonin 5-HT3 receptorsGranisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting.Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.Analysis of Dietary Intake during Consecutive-Day Chemotherapy for Bone and Soft-Tissue Sarcomas.Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.Getting it right the first time: recent progress in optimizing antiemetic usage.
P2860
Q28084970-0BD2E9CC-757B-4018-A2AA-7F24004EB3F2Q31061449-3173C678-EDB1-4116-8BBE-58AD4A229871Q34166946-2A869694-C4F8-4C4E-A030-6965CFBEE8DCQ34582576-39B2B158-25FD-4FEB-B938-25FE11707AEDQ34775395-A0D08F3E-95E9-4207-8C5D-F2E1969E7B3CQ35870991-B4766A2B-7308-4326-B611-57326CDE9425Q35871611-244D5D26-36F1-4F6A-BCBC-546185DA599EQ36524349-F462E1D1-C242-4D77-B4FF-7783930871A6Q36990036-DFAB7C74-3EA8-47BD-B89F-284A333317FCQ37551843-91F2D318-21A1-413F-B4D6-C7A214B72DEDQ37736060-E5B07B49-9C01-4844-B057-978A3BA04528Q38250191-B24D92B5-CF22-455E-B5FA-D3D263363CD3Q38260952-84D85526-908F-4CEB-A03B-334B7B97E21BQ38264147-B43E8C99-C3BB-4EB2-A946-4F590CE0FD5FQ38601381-0127DCE3-FFAA-4D29-B438-C44152777BC5Q38677762-ADCAC22C-A13C-4420-857D-89DF85C2309DQ39213490-F13E67E3-DFD8-4D66-B9B4-A458BBBE7987Q42205380-5E3663CD-462B-41B5-A522-6A9F38CF2375Q47549281-B794A3F6-E993-49E6-92AB-F5744E397C89Q47730217-E25A49AB-25F9-4FFC-9F59-50F3FE84FDB9Q47870600-076FE7EE-3065-4191-8B13-2FD73351D6F1Q49164451-D1BACBBE-EF4B-4FFE-A23B-98AFDA6B6DC6Q50101676-F8287D78-7FFB-49BE-8507-003FF1D3371BQ51738023-A6519897-F030-45EC-A060-092C8AA359D4
P2860
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pooled analysis of phase III c ...... ced nausea and vomiting (CINV)
@en
Pooled analysis of phase III c ...... ed nausea and vomiting (CINV).
@nl
type
label
Pooled analysis of phase III c ...... ced nausea and vomiting (CINV)
@en
Pooled analysis of phase III c ...... ed nausea and vomiting (CINV).
@nl
prefLabel
Pooled analysis of phase III c ...... ced nausea and vomiting (CINV)
@en
Pooled analysis of phase III c ...... ed nausea and vomiting (CINV).
@nl
P2093
P2860
P1476
Pooled analysis of phase III c ...... ced nausea and vomiting (CINV)
@en
P2093
Gary R Morrow
Gianluca Ballinari
Lee Schwartzberg
Michael D Thorn
Sally Y Barbour
P2860
P2888
P304
P356
10.1007/S00520-013-1999-9
P577
2013-10-19T00:00:00Z